Divi's Laboratories Ltd. News and Updates

Name: Latest research reports of Divi's Laboratories Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Divi's Laboratories Ltd.
Rating: 4
Author: Deven Choksey

Keep track of all breaking news on Divi's Laboratories Ltd. from all sources in a single place.

Divi's Laboratories Ltd.

13 Oct 2025

6655.00

2.20%

Divis Labs rallies 13% in 1 week; What's driving pharma stock?

Business Standard

Divis stock gained 2% in Monday's intra-day deals. Reports suggest the company is well positioned to benefit from emerging trends across both API and CDMO domains through innovation and capex.

Divi's Laboratories .. has an average target of 6414.33 from 6 brokers.

Divi's Laboratories Ltd.

10 Oct 2025

6655.00

2.20%

Pharma stocks surge as generic drugs may escape Trump tariffs

Business Line

All major pharma stocks advanced, led by Divis Laboratories, which jumped 5.05%, followed by Cipla's 2.87% gain

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

29 Aug 2025

6655.00

2.20%

Steady performance amid near-term headwinds; structural levers intact

Accumulate: Divi's Laboratories Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -14.9%/-22.7%, respectively, as we factor in subdued growth traction in Generic API segment, lower other income and higher depreciation expenses on account of higher investments in its facilities.

Divi's Laboratories Ltd. has gained 16.81% in the last 1 Month

Divi's Laboratories Ltd.

07 Aug 2025

6655.00

2.20%

Divi's Laboratories (DIVI IN) Q1FY26 Result Update Margin...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q1FY26 EBITDA was 4% below our estimates led by lower margins despite higher CS revenues. We expect margins to improve, led by better product mix and stable raw material prices. Mgmt. suggested that moderation of raw material prices, increasing RFP's and commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. Our FY26E/FY27E EPS estimates stand marginally reduced by 3-4%. We expect 20% EBITDA CAGR and 12% PAT CAGR over FY25-27E. At CMP,...

Divi's Laboratories .. has an average target of 6414.33 from 6 brokers.

Divi's Laboratories Ltd.

06 Aug 2025

6655.00

2.20%

Divi's Laboratories Results Earnings Call for Q1FY26

Conference Call with Divi's Laboratories Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.

audio

Divi's Laboratories Ltd.

19 May 2025

6655.00

2.20%

Divi's Laboratories (DIVI IN) Q4FY25 Result Update Margin...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q4FY25 EBITDA beat our estimates led by higher gross margin (62%; up 200 bps QoQ). We expect GMs to sustain, led by better product mix and stable raw material prices. Mgmt. suggested that moderation of raw material prices, increasing RFP's and commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. Our FY26E/FY27E EPS estimates broadly remain unchanged. We expect 22% EBITDA CAGR and 15% PAT CAGR over FY25-27E. At CMP, stock is trading at...

Divi's Laboratories Ltd. has gained 16.81% in the last 1 Month

Divi's Laboratories Ltd.

25 Mar 2025

6655.00

2.20%

DIVI' S LAB

Hold: Divi's Laboratories Ltd.

Target

Geojit BNP Paribas

Number of FII/FPI investors decreased from 990 to 897 in Sep 2025 qtr

Divi's Laboratories Ltd.

04 Feb 2025

6655.00

2.20%